Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study

Naveed-ur-Rehman Siddiqui, Farah Naz Qamar, Humaira Jurair, Anwarul Haque, Naveed-ur-Rehman Siddiqui, Farah Naz Qamar, Humaira Jurair, Anwarul Haque

Abstract

Background: Patients in pediatric intensive care Units (PICU) are susceptible to infections with antibiotic resistant organisms which increase the morbidity, mortality and cost of care. To describe the clinical characteristics and mortality in patients with Multi-Drug Resistant (MDR) gram negative organisms. We also report safety of Polymyxin B use in these patients.

Methods: Files of patients admitted in PICU of Aga Khan University Hospital, from January 2010 to December 2011, one month to 15 years of age were reviewed. Demographic and clinical features of patients with MDR gram negative infections, antibiotic susceptibility pattern of isolates, discharge disposition and adverse effects of Polymyxin B were recorded.

Results: A total of 44.8/1000(36/803) admitted patients developed MDR gram negative infections, of which 47.2%(17/36) were male, with mean age of 3.4 yrs(+/-4.16). Acinetobacter Species (25.5%) was the most frequently isolated MDR organisms followed by Klebsiella Pneumoniae (17%). Sensitivity of isolates was 100% to Polymyxin B, followed by Imipenem (50%), and piperacillin/tazobactem (45%). The crude mortality rate of patients with MDR gram negative infections was 44.4% (16/36). Fourteen of 36 patients received Polymyxin B and 57.1%; (8/14) of them were cured. Nephrotoxicity was observed in 21.4% (3/14) cases, none of the patients showed signs of neuropathy.

Conclusion: Our study highlights high rates of Carbapenem resistant gram negative isolates, leading to increasing use of Polymyxin B as the only drug to combat against these critically ill children. Therefore, we emphasizeon Stewardship of Antibiotics and continuous surveillance system as strategies in overall management of these critically ill children.

References

    1. Siegel RE. Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care. 2008;53(4):471–479.
    1. Fish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit Care Clin. 2006;22(2):291–311. doi: 10.1016/j.ccc.2006.02.006.
    1. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases Society of America. Clin Infect Dis. 2006;42(5):657–668. doi: 10.1086/499819.
    1. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098. doi: 10.1016/S1473-3099(13)70318-9.
    1. Souli M, Galani I, Giamarellou H: Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13(47).,
    1. System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004, 32 (8): 470-485.
    1. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005;11(Suppl 4):17–32. doi: 10.1111/j.1469-0691.2005.01161.x.
    1. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60(5):1163–1167. doi: 10.1093/jac/dkm305.
    1. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti E, Bordi D, Capozzi MP, Balice A, Tarasi G, Parisi A, Lappa A, Carattoli N. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–E30. doi: 10.1111/1469-0691.12070.
    1. Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G, Dimopoulos G, Antoniadou A, Armaganidis A, Giamarellou H. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect. 2011;17(11):E9–E11. doi: 10.1111/j.1469-0691.2011.03649.x.
    1. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Ariel P-M, Ramanan L. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis. 2005;5(9):568–580. doi: 10.1016/S1473-3099(05)70217-6.
    1. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999;33(9):960–967. doi: 10.1345/aph.18426.
    1. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin N Am. 2003;17(3):545–562. doi: 10.1016/S0891-5520(03)00058-8.
    1. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341. doi: 10.1086/429323.
    1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601. doi: 10.1016/S1473-3099(06)70580-1.
    1. Saleem AF, Qamar FN, Shahzad H, Qadir M, Zaidi AK. Trends in antibiotic susceptibility and incidence of late-onset Klebsiella pneumoniae neonatal sepsis over a six-year period in a neonatal intensive care unit in Karachi, Pakistan. Int J Infect Dis. 2013;17(11):e961–e965. doi: 10.1016/j.ijid.2013.04.007.
    1. Aman U, Rabia D, Inam U, Rafiq M. Antibiotic resistance profile of clinical gram negative bacteria. J Biol Food Sci Res. 2012;1(2):23–25.
    1. Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R. Emergence of carbapenem resistant gram negative and vancomycin resistant gram positive organisms in Bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis. 2008;8:80. doi: 10.1186/1471-2334-8-80.
    1. Wikler MA, Cockerill FR, Craig WA, Dudly MN, Eliopoulos MN, Hetch DW, Hindler JF, Low DE, Sheehan DJ, Tenover FC, Turnidge JD, Weinstein MP, Zimmer BL, Ferraro MJ, Swenson JM. Performance Standards for Antimicrobial Susceptibility Testing. 17th Information Supplement. 940 West Valley Road, Suit 1400, Wayne, Pennsylvania 19087–1998, USA: Clinical and laboratory standard institute; 2007.
    1. Koneman EW, Allen SD, Janda WM, Scherckenberger PC, JWC W. Color Atlas and Textbook of Diagnostic Microbiology: Philadelphia Lippincott. 31 West Camden Street, Baltimore MD 21201: Lippincott, Williams and Wilkins; 2002.
    1. Sachdev A, Chugh K, Sethi M, Gupta D, Wattal C, Menon G. Diagnosis of ventilator-associated pneumonia in children in resource-limited setting: a comparative study of bronchoscopic and nonbronchoscopic methods. Pediatr Crit Care Med. 2010;11(2):258–266. doi: 10.1097/PCC.0b013e3181bc5b00.
    1. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988–1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106(6):1387–1390. doi: 10.1542/peds.106.6.1387.
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi: 10.1111/j.1469-0691.2011.03570.x.
    1. Folgori L, Livadiotti S, Carletti M, Bielicki J, Pontrelli G, Degli Atti ML, Marta L, Bertaina C, Lucignano B, Ranno S, Carretto E, Muraca M, Sharland M, Bernaschi P. Epidemiology and clinical outcomes of multidrug-resistant gram-negative bloodstream infections in a european tertiary pediatric hospital during a 12-month period. Pediatr Infect Dis J. 2014;33(9):929–932. doi: 10.1097/INF.0000000000000339.
    1. Kucukates E. Antimicrobial resistance among Gram-negative bacteria isolated from intensive care units in a Cardiology Institute in Istanbul, Turkey. Jpn J Infect Dis. 2005;58(4):228–231.
    1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848–854. doi: 10.1086/432803.
    1. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005;11(1):22–29. doi: 10.3201/eid1101.040001.
    1. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 2005;18(4):306–313. doi: 10.1097/01.qco.0000171920.44809.f0.
    1. Kunz AN, Brook I. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy. 2010;56(6):492–500. doi: 10.1159/000321018.
    1. Richards M, Thursky K, Buising K. Epidemiology, prevalence, and sites of infections in intensive care units. Semin Respir Crit Care Med. 2003;24(1):3–22. doi: 10.1055/s-2003-37913.
    1. Ylipalosaari P, Ala-Kokko TI, Laurila J, Ohtonen P, Syrjala H. Intensive care acquired infection is an independent risk factor for hospital mortality: a prospective cohort study. Crit Care. 2006;10(2):R66. doi: 10.1186/cc4902.
    1. Goldmann DA, Pier GB. Pathogenesis of infections related to intravascular catheterization. Clin Microbiol Rev. 1993;6(2):176–192. doi: 10.1128/CMR.6.2.176.
    1. Ylipalosaari P, Ala-Kokko TI, Laurila J, Ohtonen P, Syrjala H. Epidemiology of intensive care unit (ICU)-acquired infections in a 14-month prospective cohort study in a single mixed Scandinavian university hospital ICU. Acta Anaesthesiol Scand. 2006;50(10):1192–1197. doi: 10.1111/j.1399-6576.2006.01135.x.
    1. Shehabi AA IB. Microbial infection and antibiotic resistance patterns among Jordanian intensive care patients. East Mediterr Health J. 1996;2:515–520.
    1. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470–480. doi: 10.1093/jac/dki248.
    1. Livermore DM. The need for new antibiotics. Clin Microbiol Infect. 2004;10(Suppl 4):1–9. doi: 10.1111/j.1465-0691.2004.1004.x.
    1. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(9):3624–3630. doi: 10.1128/AAC.49.9.3624-3630.2005.
    1. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003;47(8):2659–2662. doi: 10.1128/AAC.47.8.2659-2662.2003.
    1. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004;54(2):566–569. doi: 10.1093/jac/dkh369.
    1. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006;40(11):1939–1945. doi: 10.1345/aph.1H353.
    1. Zavascki AP, Barth AL, Goncalves AL, Moro AL, Fernandes JF, Martins AF, Ramos F, Goldani LZ. The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2006;58(2):387–392. doi: 10.1093/jac/dkl239.
    1. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. doi: 10.1186/cc3995.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe